Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers. CME information and select publications here.
--------
59:31
Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
--------
1:33:02
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy
Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. CME information and select publications here.
--------
52:52
HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer. CME information and select publications here.
--------
1:39:35
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. CME information and select publications here.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
Brasil